ETF Comparison: 2B78 vs EXV4
ETFã®èª¬æ
2B78 - iShares Healthcare Innovation UCITS ETF
The iShares Healthcare Innovation UCITS ETF is an equity fund that tracks the iSTOXX FactSet Breakthrough Healthcare index, investing in companies worldwide that are focused on innovation in global healthcare services. The fund has a total expense ratio of 0.40% and uses a sampling technique to replicate the performance of the underlying index. It is a large fund with assets under management of 982 million Euro, launched in 2016 and domiciled in Ireland.
EXV4 - iShares STOXX Europe 600 Health Care UCITS ETF (DE)
The iShares STOXX Europe 600 Health Care UCITS ETF (DE) is an equity fund that tracks the STOXX Europe 600 Health Care index, providing exposure to the European health care sector. With a total expense ratio of 0.46%, the fund replicates the performance of the underlying index through full replication and distributes dividends to investors at least annually.
æ¯èŒããŒãã«
| 2B78 | EXV4 | |
|---|---|---|
| ãã¡ã³ãå | iShares Healthcare Innovation UCITS ETF | iShares STOXX Europe 600 Health Care UCITS ETF (DE) |
| Fund Provider | BlackRock | BlackRock |
| Index | iSTOXX® FactSet Breakthrough Healthcare | STOXX® Europe 600 Health Care |
| Asset Class | Equity | Equity |
| Listing | EU-listed | EU-listed |
| Expense Ratio | 0.4% | 0.46% |
| Inception Date | 2016-09-08 | 2001-04-25 |
| Number Of Holdings | 195 | 53 |
| Currency | USD | EUR |
| Distribution Policy | Accumulating | Distributing |
| Region | Global | Europe |
| Sector | Healthcare | Healthcare |
| Sector Detail | Healthcare Innovation | Health Care |
| Leveraged | Non-leveraged | Non-leveraged |
ããã¯ãã¹ããªãã·ã§ã³
ãµããªãŒ
äž»èŠææš
ããã©ãŒãã³ã¹ææš
ãªã¹ã¯ææš
詳现ãªã¿ãŒã³
ããã©ãŒãã³ã¹åæ
ããã©ãŒãã³ã¹åæã¯ã环ç©ãªã¿ãŒã³ã幎æ«ïŒEoYïŒãªã¿ãŒã³ãSharpeã¬ã·ãªãSortinoã¬ã·ãªãªã©ã®ãªã¹ã¯èª¿æŽæžã¿ææšãéããŠãæè³æŠç¥ã®ãªã¿ãŒã³ãè©äŸ¡ããããã«éå»ããŒã¿ãè©äŸ¡ããŸããããã«ãããæè³å®¶ã¯ããŸããŸãªåžå Žç°å¢ã§ã®çµ¶å¯Ÿçããã³çžå¯Ÿçãªããã©ãŒãã³ã¹ãè©äŸ¡ã§ããŸãã
环ç©ãªã¿ãŒã³
幎æ«ãªã¿ãŒã³ããŒãã«
幎æ«ãªã¿ãŒã³
ãªã¹ã¯åæ
ãªã¹ã¯åæãšã¯ãè³æ¬ã®æå€±ã«ã€ãªããå¯èœæ§ã®ããæœåšçãªãã¬ãã£ãã€ãã³ãã®è©äŸ¡ãæããŸãããªã¹ã¯åæã宿œããããšã§ãæè³ãè¡ãã¹ããã©ããã®å€æã«åœ¹ç«ãŠãããšãã§ããŸããããã¯ãæè³æŠç¥ã®äžè²«æ§ã«å¯Ÿããå©å®³é¢ä¿è ã®ä¿¡é Œãåæ ãããããŒããŠã³ããã©ãã£ãªãã£ãããŒã¿ãªã©ã®ãªã¹ã¯ææšã䜿çšããŠè¡ãããŸãã
ãããŒããŠã³
ãããŒããŠã³ããŒãã«
ã¢ã³ãã«ã«ãã·ãã¥ã¬ãŒã·ã§ã³
ã¢ã³ãã«ã«ãã·ãã¥ã¬ãŒã·ã§ã³ã¯ãéå»ã®è³ç£äŸ¡æ ŒããŒã¿ããã®ã©ã³ãã ãµã³ããªã³ã°ãéããŠå¹ åºãæœåšçãªçµæãçæããããšã§ãããŒããã©ãªãªã®ãªã¿ãŒã³ãäºæž¬ããããã«äœ¿çšãããçµ±èšçææ³ã§ããããŸããŸãªåžå Žæ¡ä»¶äžã§ã®ããŒããã©ãªãªã®æœåšçãªãªã¹ã¯ãšãªã¿ãŒã³ãè©äŸ¡ããã®ã«åœ¹ç«ã¡ãŸãããã®ã·ãã¥ã¬ãŒã·ã§ã³ã¯åææè³ãèæ ®ããå®é¡ç©ç«ãå®é¡åŒãåºããå²ååŒãåºããªã©ã®ãã£ãã·ã¥ãããŒã·ããªãªããªãã·ã§ã³ã§ã·ãã¥ã¬ãŒãããŸãã
éèŠïŒã¢ã³ãã«ã«ãã·ãã¥ã¬ãŒã·ã§ã³ã«ãã£ãŠçæãããäºæž¬ã¯çŽç²ã«ä»®èª¬çãªãã®ã§ãããå°æ¥ã®ãªã¿ãŒã³ãä¿èšŒãããã®ã§ã¯ãããŸãããæè³å€æã¯ããŸããŸãªèŠå ãèæ ®ããäžã§è¡ãã¹ãã§ãããéå»ã®ããã©ãŒãã³ã¹ã¯å°æ¥ã®çµæã瀺ããã®ã§ã¯ãããŸããã